多西他赛在控制晚期非小细胞肺癌恶性胸腔积液的疗效和安全性评估

目的 研究多西他赛在控制晚期非小细胞肺癌恶性胸腔积液的疗效和安全性。方法 将2016年1月~12月本院接收的晚期非小细胞肺癌恶性胸腔积液患者152例，根据按照电脑随机分组原则分为两组，每组76例。两组均行胸腔穿刺术，对照组给予培美曲塞，观察组给予多西他赛治疗。将两组患者的临床疗效、不良反应发生情况和ECOG评分进行比对。结果 观察组晚期非小细胞肺癌恶性胸腔积液患者的临床总有效率89.47%，高于对照组的65.79%，差异有统计学意义（P＜0.05）；胃肠道反应、胸痛、肾毒性不良反应的发生率和治疗后ECOG评分均低于对照组，差异有统计学意义（P＜0.05）。结论 多西他赛应用在晚期非小细胞肺癌恶性胸腔积液患者中取得疗效确切，临床安全性较高。

Efficacy and Safety of Docetaxel in the Control of Malignant Pleural Effusion in Patients with Advanced Non-small Cell Lung Cancer

Abstract:Objective To study the efficacy and safety of docetaxel in the control of malignant pleural effusion in patients with advanced non-small cell lung cancer.Methods 152 patients with malignant pleural effusion of advanced non-small cell lung cancer received in our hospital from January to December 2016 were divided into two groups according to the principle of computer random grouping,76 cases in each group.Thoracic puncture was performed in both groups,pemetrexide was given in control group and docetaxel was given in observation group.The clinical efficacy,adverse reaction and ECOG score were compared between the two groups.Results The total effective rate of the patients with malignant pleural effusion of non-small cell lung cancer in the observation group was 89.47%,which was higher than that of the control group 65.79%,the difference was statistically significant(P<0.05).The incidence of gastrointestinal reactions,chest pain and nephrotoxic adverse reactions and the ECOG score after treatment were lower than those of the control group,the difference was statistically significant(P<0.05).Conclusion Docetaxel is effective and safe in the treatment of advanced non-small cell lung cancer with malignant pleural effusion.